M2 TAMs upregulated SGLT1 expression in BC cells via the EGFR/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, leading to tamoxifen resistance and accelerating tumor growth both in vitro and in vivo, while the depletion of M2 TAMs induced the opposite effects. This evidence concerns the gene SLC5A1 and breast cancer.